
Najib M. Rahman
Articles
-
Nov 12, 2024 |
publications.ersnet.org | Beenish Iqbal |Eihab O. Bedawi |Najib M. Rahman
IntroductionWe start with a scenario. A patient has been given 3–4 months' life expectancy and has to make a choice between two treatments for their recurring malignant pleural effusion (MPE): one which requires hospital admission for 4–5 days and still might not work versus a “one-off” procedure with home drainage. Which one sounds better?
-
Oct 23, 2024 |
bmj.com | Najib M. Rahman |James Ware |Rupert Woolley
Rupert Woolley, Najib Rahman, James Ware Woolley R, Rahman N, Ware J. John Matthew Wrightson BMJ 2024; 387 :q2290 doi:10.1136/bmj.q2290
-
Jun 27, 2024 |
bmjopenrespres.bmj.com | Catherine Henshall |Paul Dawson |Najib M. Rahman |Hannah Ball
Understanding clinical decision-making in mesothelioma care: a mixed methods study Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Apr 1, 2024 |
nature.com | Pablo F. Céspedes |Uzi Gileadi |Zhu Liang |Fei Gao |Nikolaos Kanellakis |Yi-Ling Chen | +7 more
AbstractCancer remains one of the leading causes of mortality worldwide, leading to increased interest in utilizing immunotherapy strategies for better cancer treatments. In the past decade, CD103+ T cells have been associated with better clinical prognosis in patients with cancer. However, the specific immune mechanisms contributing toward CD103-mediated protective immunity remain unclear.
-
Feb 23, 2024 |
nature.com | Joseph F Standing |Laura Buggiotti |Claire Smith |Theo Sanderson |Fiona Ashford |Adrian Shields | +13 more
AbstractViral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n = 253) or Usual Care (n = 324) were recruited to study viral and antibody dynamics and the effect of molnupiravir on viral whole genome sequence from 1437 viral genomes. Molnupiravir accelerates viral load decline, but virus is detectable by Day 5 in most cases.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →